These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12693434)

  • 1. A randomized single-blind pilot study of compensatory strategies in schizophrenia outpatients.
    Velligan DI; Prihoda TJ; Ritch JL; Maples N; Bow-Thomas CC; Dassori A
    Schizophr Bull; 2002; 28(2):283-92. PubMed ID: 12693434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia.
    Velligan DI; Bow-Thomas CC; Huntzinger C; Ritch J; Ledbetter N; Prihoda TJ; Miller AL
    Am J Psychiatry; 2000 Aug; 157(8):1317-23. PubMed ID: 10910797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is cognitive adaptation training (CAT) compensatory, restorative, or both?
    Fredrick MM; Mintz J; Roberts DL; Maples NJ; Sarkar S; Li X; Velligan DI
    Schizophr Res; 2015 Aug; 166(1-3):290-6. PubMed ID: 26126419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving functional outcomes for schizophrenia patients in the Netherlands using Cognitive Adaptation Training as a nursing intervention - A pilot study.
    Quee PJ; Stiekema AP; Wigman JT; Schneider H; van der Meer L; Maples NJ; van den Heuvel ER; Velligan DI; Bruggeman R
    Schizophr Res; 2014 Sep; 158(1-3):120-5. PubMed ID: 25000912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia.
    Velligan DI; Diamond PM; Maples NJ; Mintz J; Li X; Glahn DC; Miller AL
    Schizophr Res; 2008 Jul; 102(1-3):312-9. PubMed ID: 18374542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The short-term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia.
    Velligan DI; Diamond P; Mueller J; Li X; Maples N; Wang M; Miller AL
    Psychiatry Res; 2009 Jul; 168(2):94-101. PubMed ID: 19523690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.
    Hogarty GE; Flesher S; Ulrich R; Carter M; Greenwald D; Pogue-Geile M; Kechavan M; Cooley S; DiBarry AL; Garrett A; Parepally H; Zoretich R
    Arch Gen Psychiatry; 2004 Sep; 61(9):866-76. PubMed ID: 15351765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial.
    Wykes T; Newton E; Landau S; Rice C; Thompson N; Frangou S
    Schizophr Res; 2007 Aug; 94(1-3):221-30. PubMed ID: 17524620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive training for divergent thinking in schizophrenia: a pilot study.
    Nemoto T; Yamazawa R; Kobayashi H; Fujita N; Chino B; Fujii C; Kashima H; Rassovsky Y; Green MF; Mizuno M
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1533-6. PubMed ID: 19733608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive rehabilitation for schizophrenia.
    Kurtz MM
    Curr Psychiatry Rep; 2003 Aug; 5(4):303-10. PubMed ID: 12857534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive adaptation training for outpatients with schizophrenia.
    Draper ML; Stutes DS; Maples NJ; Velligan DI
    J Clin Psychol; 2009 Aug; 65(8):842-53. PubMed ID: 19521972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia.
    Granholm E; McQuaid JR; McClure FS; Auslander LA; Perivoliotis D; Pedrelli P; Patterson T; Jeste DV
    Am J Psychiatry; 2005 Mar; 162(3):520-9. PubMed ID: 15741469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial examining a cognitive behavioral therapy intervention enhanced with cognitive remediation to improve work and neurocognition outcomes among persons with schizophrenia spectrum disorders.
    Kukla M; Bell MD; Lysaker PH
    Schizophr Res; 2018 Jul; 197():400-406. PubMed ID: 29422299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cognitive remediation on neurocognitive functions and psychiatric symptoms in schizophrenia inpatients.
    Gharaeipour M; Scott BJ
    Schizophr Res; 2012 Dec; 142(1-3):165-70. PubMed ID: 23102691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REPYFLEC cognitive remediation group training in schizophrenia: Looking for an integrative approach.
    Farreny A; Aguado J; Ochoa S; Huerta-Ramos E; Marsà F; López-Carrilero R; Carral V; Haro JM; Usall J
    Schizophr Res; 2012 Dec; 142(1-3):137-44. PubMed ID: 23017827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compensatory cognitive training for people with first-episode schizophrenia: results from a pilot randomized controlled trial.
    Mendella PD; Burton CZ; Tasca GA; Roy P; St Louis L; Twamley EW
    Schizophr Res; 2015 Mar; 162(1-3):108-11. PubMed ID: 25631454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.
    Velligan DI; Prihoda TJ; Sui D; Ritch JL; Maples N; Miller AL
    J Clin Psychiatry; 2003 May; 64(5):524-31. PubMed ID: 12755654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.
    Velligan DI; Roberts D; Mintz J; Maples N; Li X; Medellin E; Brown M
    Schizophr Res; 2015 Jul; 165(2-3):175-80. PubMed ID: 25937461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
    F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
    Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.